GSK To Take ‘Smart Risks’ Across Portfolio – But Will Be ‘Pragmatic’ About Oncology Expansion
US FDA Sets May 2023 Decision Date For RSV Vaccine
Executive Summary
GSK’s new R&D leader, Tony Wood, has promised a more hard-nosed attitude to picking winners – including a ‘pragmatic’ approach to the hyper-competitive field of oncology.
You may also be interested in...
GSK Tries To Chase Down Pfizer With Phase III Pentavalent Meningococcal Vaccine Data
Phase III data for a vaccine combining Bexsero and Menveo demonstrated non-inferiority. GSK hopes to file it for approval soon, while Pfizer’s candidate has an October FDA action date.
GSK Unveils Plans For New Global HQ In Central London
GSK is returning to its central London roots with a smaller but more modern HQ, while property developers are planning a huge new lab space and research hub in Canary Wharf.
Blenrep US Withdrawal Is A Big Blow To GSK’s Blockbuster Hopes
Blenrep’s withdrawal will add to GSK’s blockbuster drought, and hopes of separate trial success for the BCMA-targeting drug in earlier stage myeloma may now be harder to achieve.